Related references
Note: Only part of the references are listed.Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis
Xi Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
Fatemeh K. Dermani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Martin Reck et al.
FUTURE ONCOLOGY (2019)
Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway
Chunrong Zhang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells
Thijs S. Stutvoet et al.
JOURNAL OF PATHOLOGY (2019)
Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma
Christelle Vincent-Fabert et al.
CELL COMMUNICATION AND SIGNALING (2019)
Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
Anquan Shang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Heterogeneity-of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
Alexander Haragan et al.
LUNG CANCER (2019)
LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
Lina Zhao et al.
CELL DEATH & DISEASE (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
Antonio Santaniello et al.
CANCERS (2019)
The role of exosomal PD-L1 in tumor progression and immunotherapy
Feiting Xie et al.
MOLECULAR CANCER (2019)
Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials
Jong Yeob Kim et al.
CANCERS (2019)
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
Yongfeng Wu et al.
FRONTIERS IN ONCOLOGY (2019)
Association of PD-L1 gene rs4143815 C > G polymorphism and human cancer susceptibility: A systematic review and meta-analysis
Ju Zou et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis
Shuquan Wei et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2019)
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
PD-1 and cancer: molecular mechanisms and polymorphisms
Arash Salmaninejad et al.
IMMUNOGENETICS (2018)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Palanisamy Nallasamy et al.
SEMINARS IN CANCER BIOLOGY (2018)
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
Maria Bassanelli et al.
ANTICANCER RESEARCH (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression
Wen-Hao Yang et al.
CANCER RESEARCH (2018)
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
Meixuan Chen et al.
CLINICAL BREAST CANCER (2018)
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
Wei Xiao et al.
JOURNAL OF IMMUNOLOGY (2018)
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes et al.
ONCOGENE (2018)
Epigenetic regulators of programmed death-ligand 1 expression in human cancers
Sachin Kumar et al.
TRANSLATIONAL RESEARCH (2018)
PD-L1 expression is regulated by both DNA methylation and NF-kappa B during EMT signaling in non-small cell lung carcinoma
A. Asgarova et al.
ONCOIMMUNOLOGY (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer
Hye Kyoung Yoon et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
Federico Pio Fabrizio et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Jung-Mao Hsu et al.
CANCER RESEARCH (2018)
A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer
Li-Hua Tao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
Qingshui Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape
Stefan B. Eichmueller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
MYC: Master Regulator of Immune Privilege
Stephanie C. Casey et al.
TRENDS IN IMMUNOLOGY (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma
Hyein Ahn et al.
ONCOTARGET (2017)
Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape
Stefan B. Eichmueller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
Henrick Horita et al.
NEOPLASIA (2017)
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma
Jan Budczies et al.
ONCOIMMUNOLOGY (2017)
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Jan Budczies et al.
BMC MEDICAL GENOMICS (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation
Nuala A. O'Leary et al.
NUCLEIC ACIDS RESEARCH (2016)
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore et al.
CLINICAL CANCER RESEARCH (2016)
Pan-Cancer Analysis of Copy Number Changes in Programmed Death-Ligand 1 (PD-L1, CD274) - Associations with Gene Expression, Mutational Load, and Survival
Jan Budczies et al.
GENES CHROMOSOMES & CANCER (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
Zsofia K. Stadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer
Seiichi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Benjamin V. Park et al.
CANCER DISCOVERY (2016)
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
Melanie Straub et al.
ONCOTARGET (2016)
Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
Yusuke Inoue et al.
ONCOTARGET (2016)
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
Subrata Chowdhury et al.
ONCOTARGET (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies
B. Seliger
HLA (2016)
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
Brooke E. Howitt et al.
JAMA ONCOLOGY (2016)
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
Jin S. Im et al.
PLOS ONE (2016)
The role of MicroRNAs in human cancer
Yong Peng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Kailong Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Z. Sun et al.
CANCER RESEARCH (2015)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism
Victor Tkachev et al.
JOURNAL OF IMMUNOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Nikolaos Patsoukis et al.
NATURE COMMUNICATIONS (2015)
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Michael T. Barrett et al.
ONCOTARGET (2015)
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Kavitha Gowrishankar et al.
PLOS ONE (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
BLOOD (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
Odey C. Ukpo et al.
HEAD & NECK PATHOLOGY (2013)
A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding
Weipeng Wang et al.
HUMAN MUTATION (2012)
Soluble B7-H1: Differences in production between dendritic cells and T cells
Xavier Frigola et al.
IMMUNOLOGY LETTERS (2012)
Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
Nikolaos Patsoukis et al.
SCIENCE SIGNALING (2012)
B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma
Dong Hua et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule
Hazem Ghebeh et al.
BREAST CANCER RESEARCH (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched forVH11/VH12 and phosphatidylcholine binding
Xuemei Zhong et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
T-cell tolerance or function is determined by combinatorial costimulatory signals
Roza Nurieva et al.
EMBO JOURNAL (2006)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Trophoblast CD274 (B7-H1) is differentially expressed across gestation: Influence of oxygen concentration
LM Holets et al.
BIOLOGY OF REPRODUCTION (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy
N Selenko-Gebauer et al.
JOURNAL OF IMMUNOLOGY (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
